

Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Diclofenac potassium powder, for oral solution (Cambia)

Notes:

- *Adequate trial for triptan requires use in at least 3 acute migraine attacks. If pain reduction occurs in 2 out of 3 episodes, the medication is considered effective.

Initiation (new start) criteria: Non-formulary **diclofenac potassium powder for oral solution (Cambia)** will be covered on the prescription drug benefit when the following criteria for new therapy, stable or new member coverage are met:

- Prescribed for treatment of acute migraine by or in consultation with a headache specialist
- Documented clinically significant intolerance, treatment failure* or contraindication to sumatriptan, rizatriptan and naratriptan.
- Documented clinically significant intolerance, treatment failure or contraindication to acetaminophen
- Documented clinically significant intolerance, treatment failure or contraindication to four formulary NSAIDs (ibuprofen, naproxen, meloxicam, etodolac, nabumetone, indomethacin)
- Documented clinically significant intolerance or treatment failure to diclofenac tablets (e.g. diclofenac sodium DR or 24hr SR) that would be expected to improve with powder formulation
- Documented clinically significant intolerance or treatment failure to diclofenac capsule (e.g. Zorvolex) that would be expected to improve with powder formulation